Duke partner Raleigh Neurology Associates enrolls 100th MS patient

Raleigh Neurology Associates recently reached the 100-patient milestone for the MURDOCK Multiple Sclerosis Study, a long-term health research project based at the North Carolina Research Campus in Kannapolis, N.C. Raleigh Neurology partnered with Duke in July 2014 to help recruit 1,000 people with multiple sclerosis and 100 people with Primary Progressive MS. The sixth largest MS practice in the country, Raleigh Neurology has even a hired a new part-time coordinator dedicated to MURDOCK Study enrollment.

Simon Gregory, PhD is principal investigator for the MURDOCK Multiple Sclerosis Study and associate professor at the Duke Molecular Physiology Institute at Duke University School of Medicine. He and his team are working to identify the genetic underpinnings of complex diseases like MS and understand disease development and progression at the molecular level.

“Working with Duke and the MURDOCK Study team has been truly exciting for Raleigh Neurology Associates and our patients. We currently have dozens of late phase clinical research ongoing, so being involved in genetic, molecular level research is exciting—especially with Duke University,” said Sean Walsh, director of Clinical Research for Raleigh Neurology. “Through this partnership, our patients have been able to easily participate in Dr. Gregory’s research, which we hope will lead to groundbreaking discoveries to enhance the quality of life for future generations."

Without a cure or diagnostic test, multiple sclerosis remains a mysterious and unpredictable disease affecting as many as 400,000 people in the United States who suffer symptoms ranging from numbness and tingling to blindness and paralysis. When someone has MS, his or her own immune system directs an abnormal response against the central nervous system.